-
2026-10-28
IND Approval: GenSci136 Advances into Sj?gren's SyndromeLearn More
-
2026-10-22
Phase 3 trial in China successfully confirms ACARIZAX? safety and efficacy in patients with house dust mite allergyLearn More
-
2026-10-10
GenSci's Oncology Innovation: NDA Approval Secured for Prostate CancerLearn More
-
2026-10-09
GenSci's Two Innovations Received IND Clearance from NMPALearn More
-
2026-09-03
GenSci Showcases Innovation at CPHI Korea 2026Learn More
-
2026-03-17
Positive Phase II Results for GenSci's Firsekibart in Pediatric Rare Disease PublishedLearn More
-
2026-03-11
GenSci128, an Investigational Cancer Therapy from Gensci Pharmaceuticals, Receives FDA Orphan Drug Designation for Pancreatic CancerLearn More
-
2026-02-14
GenSci136, an APRIL/BAFF Dual Antagonist, Granted Clinical Trial Approval for IgANLearn More
-
2026-01-16
GenSci Unveils Seven Innovative Pipeline at JPM 2026Learn More
-
2025-12-23
GenSci Partners with Leading AI Company Partex AI to Accelerate Drug Development and Global CommercializationLearn More
-
2025-12-16
GenSci Secures Up to $1.365B in Global ex-China Licensing Deal for GS-098(YB-101) with RTW InvestmentsLearn More